Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)

BACKGROUND: A phase II clinical trial of the comparison between eribulin plus gemcitabine (EG) and paclitaxel plus gemcitabine (PG) as first-line chemotherapy for patients with metastatic breast cancer (MBC) found that the EG regimen was less neurotoxic, but was similar in efficacy to the PG regimen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Commun (Lond)
Main Authors: Kim, Ji-Yeon, Park, Seri, Im, Seock-Ah, Kim, Sung-Bae, Sohn, Joohyuk, Lee, Keun Seok, Chae, Yee Soo, Lee, Ki Hyeong, Kim, Jee Hyun, Im, Young-Hyuck, Kim, Tae-Yong, Lee, Kyung-Hun, Ahn, Jin-Hee, Kim, Gun Min, Park, In Hae, Lee, Soo Jung, Han, Hye Sook, Kim, Se Hyun, Jung, Kyung Hae, Park, Yeon Hee
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6540535/
https://ncbi.nlm.nih.gov/pubmed/31138332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-019-0375-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados